These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 10867532)

  • 1. Effect of acarbose on blood glucose and proteinuria in patients with diabetic nephropathy.
    Tomino Y; Shirato I; Horikoshi S; Fukui M; Yamaguchi Y; Yokomatsu M; Ebihara I; Shimada N; Hishiki T; Hirano K; Rinno H; Shiota J; Kuramoto T
    Nephron; 2000 Jun; 85(2):190. PubMed ID: 10867532
    [No Abstract]   [Full Text] [Related]  

  • 2. [Acarbose--an effective drug for the prevention of type 2 diabetes and cardiovascular diseases?].
    Laakso M
    Duodecim; 2003; 119(20):1921-3. PubMed ID: 14639996
    [No Abstract]   [Full Text] [Related]  

  • 3. [Dangerous blood glucose peaks. Vascular damage even before diabetes].
    MMW Fortschr Med; 2003 Sep; 145(35-36):53. PubMed ID: 14584214
    [No Abstract]   [Full Text] [Related]  

  • 4. Effects of a single administration of acarbose on postprandial glucose excursion and endothelial dysfunction in type 2 diabetic patients: a randomized crossover study.
    Shimabukuro M; Higa N; Chinen I; Yamakawa K; Takasu N
    J Clin Endocrinol Metab; 2006 Mar; 91(3):837-42. PubMed ID: 16368744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Type II Diabetes Patients with Proteinuria and the Recovery of Their Metabolic Parameters.
    Ya-Zhuo L; Keqi W; Xiang L; Bin C
    Cell Biochem Biophys; 2015 Dec; 73(3):593-5. PubMed ID: 27259298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Role of acarbose in the treatment of diabetes mellitus].
    Scheen AJ
    Diabetes Metab; 1998 Sep; 24(4):385-90. PubMed ID: 9805654
    [No Abstract]   [Full Text] [Related]  

  • 7. [Reducing postprandial glucose levels. Glucosidase antagonists].
    Neye H
    Pharm Unserer Zeit; 2002; 31(3):272-8. PubMed ID: 12071124
    [No Abstract]   [Full Text] [Related]  

  • 8. [Even if fasting blood glucose value is quite normal, proceed with a glucose tolerance test].
    MMW Fortschr Med; 2002 May; 144(20):65. PubMed ID: 12125660
    [No Abstract]   [Full Text] [Related]  

  • 9. Which hypoglycaemic agents to use in type 2 diabetic subjects with CKD and how?
    Haneda M; Morikawa A
    Nephrol Dial Transplant; 2009 Feb; 24(2):338-41. PubMed ID: 19015168
    [No Abstract]   [Full Text] [Related]  

  • 10. Dual therapy of vildagliptin and telmisartan on diabetic nephropathy in experimentally induced type 2 diabetes mellitus rats.
    Sharma AK; Kanawat DS; Mishra A; Dhakad PK; Sharma P; Srivastava V; Joshi S; Joshi M; Raikwar SK; Kurmi MK; Srinivasan BP
    J Renin Angiotensin Aldosterone Syst; 2014 Dec; 15(4):410-8. PubMed ID: 23396552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Acarbose for prevention of diabetes mellitus. STOP-NIDDM]].
    Windler E
    Internist (Berl); 2003 Apr; 44(4):491-3. PubMed ID: 12914407
    [No Abstract]   [Full Text] [Related]  

  • 12. Microvascular disease: what does the UKPDS tell us about diabetic nephropathy?
    Bilous R
    Diabet Med; 2008 Aug; 25 Suppl 2():25-9. PubMed ID: 18717975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Thus to avoid complications of diabetes. To combine early].
    MMW Fortschr Med; 2001 Nov; 143(44):60. PubMed ID: 11732409
    [No Abstract]   [Full Text] [Related]  

  • 14. Effect of acarbose on glycemic control, serum lipids and lipoproteins in type 2 diabetes.
    Mughal MA; Memon MY; Zardari MK; Tanwani RK; Ali M
    J Pak Med Assoc; 2000 May; 50(5):152-6. PubMed ID: 11242714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acarbose treatment and diabetic nephropathy in the Cohen diabetic rat.
    Cohen AM; Rosenmann E
    Horm Metab Res; 1990 Oct; 22(10):511-5. PubMed ID: 2079312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in the treatment of diabetic nephropathy.
    Cherney DZ
    Nephrol News Issues; 2013 Apr; 27(5):18, 33. PubMed ID: 23638530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulating effect of atorvastatin on paraoxonase 1 activity in type 2 diabetic Egyptian patients with or without nephropathy.
    Abdin AA; Hassanien MA; Ibrahim EA; El-Noeman Sel-D
    J Diabetes Complications; 2010; 24(5):325-33. PubMed ID: 19553142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Acarbose on Glycemic Variability in Patients with Poorly Controlled Type 2 Diabetes Mellitus Receiving Stable Background Therapy: A Placebo-Controlled Trial.
    Derosa G; Franzetti I; Querci F; D'Angelo A; Maffioli P
    Pharmacotherapy; 2015 Nov; 35(11):983-90. PubMed ID: 26598090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial.
    Chiasson JL; Josse RG; Gomis R; Hanefeld M; Karasik A; Laakso M;
    JAMA; 2003 Jul; 290(4):486-94. PubMed ID: 12876091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of acarbose administration on plasma concentrations of zinc and copper in patients with NIDDM.
    Song YM; Chen MD; Sheu WH
    Kaohsiung J Med Sci; 2000 Apr; 16(4):187-91. PubMed ID: 10933749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.